Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2016-12-31, filed 2017-02-14, with 35 holding rows worth $486,757,000.

Accession
0000930413-17-000546
Filed
2017-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2016

A holdings report, 35 entries on the cover page, a total value of $486,757,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $486,757,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ADAMAS PHARMACEUTICALS INC00548A106COM2,601,351$43,963,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS3,000,000$33,300,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM2,010,000$32,060,000thousands by filing date
SYNERGY PHARMACEUTICALS DEL871639308COM NEW4,973,509$30,289,000thousands by filing date
ZOGENIX INC.98978L204Common Stock2,440,959$29,658,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM750,000$29,025,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM828,253$27,746,000thousands by filing date
MEDICINES CO584688105COM750,000$25,455,000thousands by filing dateput
IGNYTA INC451731103COM4,000,000$21,200,000thousands by filing date
MERRIMACK PHARMACEUTICALS IN590328100COM5,000,000$20,400,000thousands by filing date
AVEXIS INC05366U100COM413,179$19,721,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM385,683$19,693,000thousands by filing date
THERAPEUTICSMD INC88338N107COM3,276,010$18,903,000thousands by filing date
TREVENA INC89532E109COM3,000,650$17,644,000thousands by filing date
COLUCID PHARMACEUTICALS INC19716T101COM437,865$15,938,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM1,000,000$14,450,000thousands by filing date
DBV TECHNOLOGIES S A23306J101ADR370,000$12,998,000thousands by filing date
BOVIE MEDICAL CORP10211F100COM3,055,000$10,967,000thousands by filing date
Rocket Pharmaceuticals Inc45780V102SHS1,500,000$9,150,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM270,000$7,787,000thousands by filing date
CONNECTURE INC COM20786J106Stock4,127,232$6,934,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM1,537,873$5,567,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock725,000$4,589,000thousands by filing dateput
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO350,000$4,354,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM870,261$4,134,000thousands by filing date
OCERA THERAPEUTICS INC COM67552A108COM1,963,777$4,124,000thousands by filing date
DERMIRA INC24983L104COM114,080$3,460,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock500,000$3,165,000thousands by filing datecall
ALIMERA SCIENCES INC016259103COM2,293,675$2,477,000thousands by filing date
TENAX THERAPEUTICS INC88032L100COM1,108,593$2,162,000thousands by filing date
CATABASIS PHARMACEUTICALS IN14875P107COM556,537$2,009,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock51,935$1,944,000thousands by filing date
ARADIGM CORP038505400COM NO PAR NEW791,870$1,267,000thousands by filing date
STREAMLINE HEALTH SOLUTIONS86323X106COM151,611$190,000thousands by filing date
OPHTHOTECH CORP683745103COM7,100$34,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-17-000546this filing2017-02-14acceptance time not in the bulk data set